Tempus AI may be about to go on a run, and its short interest looks a bit rich. As of June 15, 38M of its 180M shares outstanding were sold short, a roughly $2B position at $54. x.com 

Tempus AI's selloff after it beat and raised guidance looks like a great deal, and a further drop would be a chance to buy more. x.com 

Tempus AI is a short idea because the stock is being pumped on recent FDA clearances for its EKG-AI tools, while the revenue from them is far off and may never materialize. x.com 

Tempus AI is being repriced because its acquisition of Personalis benefits directly from positive Moderna news, while short covering is still underway. Short interest is about 30 million shares, over eight days of normal 3-5 million share volume, and the three-day surge absorbed under a third of it. A small market cap makes the stock easy to push higher, and bullish divergences on the three-day and weekly charts usually last weeks to months. Resistance sits at 74-76, 80 and 84-86. x.com  x.com  … Show more

Tempus AI is one of the highest-conviction setups now, and the widespread doubt about its move is itself bullish. The skepticism was earned by a year of false starts, but clearing $58 should flip sentiment quickly, with a near-term target of $68-$73. A weekly break above $73 sets a medium- to long-term target of $144-$168. Momentum is building on both lower and higher timeframes, while about 38M shares, roughly 28% of the float, are sold short into the breakout. x.com  x.com  x.com 

Tempus AI is a second- or third-tier genomic lab whose AI story is marketing mumbo jumbo, and its management team are promoters. x.com 

Tempus AI's chart points to $90 and then $100 if it clears the $85 call wall. It broke out of a falling wedge after three bottoms near $41.73, is up 58.9% over 30 sessions and is back above the 0.618 Fibonacci level at $80.41. Options are cheap, with implied volatility of 77 against realized volatility of 85. x.com 

Tempus AI could catch a bid as a laggard in the hot medical AI space, and it could catch fire soon. Its setup is getting too hard to ignore, despite plenty of past scars on the name. x.com  x.com  x.com 

AI-for-science stocks show a typical pump-and-dump setup driven by Chinese and Hong Kong hedge funds, and more pumps and dumps are likely. These funds trade narratives and price in an extremely bright future, so consensus forms fast and crowded positions reverse easily. When Chinese sell-side analysts or the Chinese community on X are loud about a thesis, it is a trade to avoid. Fundamentals still look exciting, and key moving averages are the signal to re-enter long. x.com  x.com 

Tempus AI has a data moat no one has replicated: a multimodal, patient-linked genomic, clinical and imaging dataset at scale. It holds over 8 million imaging files, 1.5 million matched clinical and molecular profiles and 4.5 million sequencing samples, which drug companies leaning on AI increasingly need. It is expanding from oncology into cardiology, neuropsychiatry and radiology. Revenue grows 25% and gross margin rose from 32% in 2021 to 64%, though last quarter's profit was a one-time item. … Show more